pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2013-0-2-5-9pulmo-153Research ArticleПЕРЕДОВАЯ СТАТЬЯEDITORIALПолиморфизм гена ADRB2: роль в предрасположенности к заболеванию, тяжести течения и терапевтическом ответе при хронической обструктивной болезни легкихADRB2 gene polymorphism: a role for predisposition, course and therapeutic response in chronic obstructive pulmonary diseaseЦветковаО. А.TsevtkovaO. A.

д. м. н., проф. кафедры госпитальной терапии № 1 лечебного факультета

119991, Москва, ул. Трубецкая, 8, стр. 2. Тел.: 8 (916) 570-38-80.

МустафинаМ. Х.MustafinaM. Kh.

аспирант кафедры госпитальной терапии № 1 лечебного факультета

119991, Москва, ул. Трубецкая, 8, стр. 2. Тел.: 8 (916) 478-59-42.

ГБОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава РоссииRussian Federation2013280420130259Copyright © Цветкова О.А., Мустафина М.Х., 20132013Цветкова О.А., Мустафина М.Х.Tsevtkova O.A., Mustafina M.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/153

Полиморфизм гена ADRB2: роль в предрасположенности к заболеванию, тяжести течения и терапевтическом ответе при хронической обструктивной болезни легких.

ADRB2 gene polymorphism: a role for predisposition, course and therapeutic response in chronic obstructive pulmonary disease.

хроническая обструктивная болезнь легкихβ2-адренергический рецепторполиморфизм гена ADRB2ответ на терапию при ХОБЛβ2-агонистыфармакогенетикаCOPDβ2-adrenergic receptorADRB2 polymorphismtherapeutic response in COPDβ2-agonistspharmacogeneticsReferencesNowak D., Berger K., Lippert B. et al. Epidemiology and health economics of COPD across Europe. Treat. Respir. Med. 2005; 4: 381–395.Nowak D., Berger K., Lippert B. et al. Epidemiology and health economics of COPD across Europe. Treat. Respir. Med. 2005; 4: 381–395.Davis R.M., Novotny T.E. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1989; 140: 82–84.Davis R.M., Novotny T.E. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1989; 140: 82–84.Joos L., Weir T.D., Connett J.E. et al. Polymorphisms in the β2-adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers. Thorax 2003; 58: 703–707.Joos L., Weir T.D., Connett J.E. et al. Polymorphisms in the β2-adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers. Thorax 2003; 58: 703–707.Sampsonas F., Karkoulias K., Kaparianos A., Spiropoulos K. Genetics of chronic obstructive pulmonary disease, beyond alpha1-antitrypsin deficiency. Curr. Med. Chem. 2006; 13: 2857–2873.Sampsonas F., Karkoulias K., Kaparianos A., Spiropoulos K. Genetics of chronic obstructive pulmonary disease, beyond alpha1-antitrypsin deficiency. Curr. Med. Chem. 2006; 13: 2857–2873.Joos L., Pare′ P.D., Sandford A.J. Genetic risk factors for chronic obstructive pulmonary disease. Swiss. Med. Wkly 2002; 132: 27–37.Joos L., Pare′ P.D., Sandford A.J. Genetic risk factors for chronic obstructive pulmonary disease. Swiss. Med. Wkly 2002; 132: 27–37.Silverman E.K., Chapman H.A., Drazen J.M. et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am. J. Respir. Crit. Care Med. 1998; 57: 1770–1778.Silverman E.K., Chapman H.A., Drazen J.M. et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am. J. Respir. Crit. Care Med. 1998; 57: 1770–1778.Tierney L.M., McPhee S.J., Papadakis M.A. et al. Current medical diagnosis and treatment. Stamford, CT: Appleton and Lange; 1997. 241–260Tierney L.M., McPhee S.J., Papadakis M.A. et al. Current medical diagnosis and treatment. Stamford, CT: Appleton and Lange; 1997. 241–260Barnes P.J., Lee T.H. Recent advances in asthma. Postgrad. Med. J. 1992; 68: 942–953.Barnes P.J., Lee T.H. Recent advances in asthma. Postgrad. Med. J. 1992; 68: 942–953.Kobilka B.K., Dixon R.A., Frielle H.G. et al. cDNA for the human β2-adrenoreceptor; a protein with multiple membrane spanning domains and encoded by a gene whose chromosomal location is shared by the receptor for plateletderived growth factor. Proc. Natl. Acad. Sci. USA 1987; 84: 46–50.Kobilka B.K., Dixon R.A., Frielle H.G. et al. cDNA for the human β2-adrenoreceptor; a protein with multiple membrane spanning domains and encoded by a gene whose chromosomal location is shared by the receptor for plateletderived growth factor. Proc. Natl. Acad. Sci. USA 1987; 84: 46–50.Reihsaus E., Innis M., MacIntyre N. et al. Mutations in the gene coding for the β2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell. Mol. Biol. 1993; 8: 334–339.Reihsaus E., Innis M., MacIntyre N. et al. Mutations in the gene coding for the β2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell. Mol. Biol. 1993; 8: 334–339.Liggett S.B. Polymorphisms of the β2-adrenergic receptor and asthma. Am. J. Respir. Crit. Care Med. 1997; 156: 5156–5162.Liggett S.B. Polymorphisms of the β2-adrenergic receptor and asthma. Am. J. Respir. Crit. Care Med. 1997; 156: 5156–5162.Hall I.P. β2-adrenoceptor polymorphisms: are they clinically important? Thorax 1996; 51: 351–353.Hall I.P. β2-adrenoceptor polymorphisms: are they clinically important? Thorax 1996; 51: 351–353.Turki J., Pak J., Green S.A. et al. Genetic polymorphisms of the β2-adrenergic receptor in nocturnal and nonnocturnal asthma: evidence that Gly16 correlates with the nocturnal phenotype. J. Clin. Invest. 1995; 95: 1635–1641.Turki J., Pak J., Green S.A. et al. Genetic polymorphisms of the β2-adrenergic receptor in nocturnal and nonnocturnal asthma: evidence that Gly16 correlates with the nocturnal phenotype. J. Clin. Invest. 1995; 95: 1635–1641.Green S.A., Turki J., Innis M. et al. Amino-terminal polymorphisms of the human β2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414–9419.Green S.A., Turki J., Innis M. et al. Amino-terminal polymorphisms of the human β2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414–9419.Hall I.P., Wheatley A., Wilding P. et al. Association of the Glu27 β2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995; 345: 1213–1214.Hall I.P., Wheatley A., Wilding P. et al. Association of the Glu27 β2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995; 345: 1213–1214.Dewar J.C., Wilkinson J., Wheatley A. et al. The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J. Allergy Clin. Immunol. 1997; 100: 261–265.Dewar J.C., Wilkinson J., Wheatley A. et al. The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J. Allergy Clin. Immunol. 1997; 100: 261–265.Hizawa N., Makita H., Nasuhara Y. et al. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 2007; 132: 1485–1492.Hizawa N., Makita H., Nasuhara Y. et al. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 2007; 132: 1485–1492.Hersh C.P. Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics 2010; 11 (2): 237–247.Hersh C.P. Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics 2010; 11 (2): 237–247.Vacca G., Schwabe K. Polymorphisms of the β2-adrenoreceptor gene in chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis. 2009; 3: 3.Vacca G., Schwabe K. Polymorphisms of the β2-adrenoreceptor gene in chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis. 2009; 3: 3.Ho L.+I., Harn H.+J., Chen C.+H., Tsai N.+M. Polymorphism of the β2-adrenoceptor in COPD in Chinese subjects. Chest 2001; 120: 1493–1499.Ho L.+I., Harn H.+J., Chen C.+H., Tsai N.+M. Polymorphism of the β2-adrenoceptor in COPD in Chinese subjects. Chest 2001; 120: 1493–1499.Kim W.J., Oh Y.M., Sung J. et al. Lung function response to 12-week treatment with combined inhalation of long-acting β2-agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008; 186 (6): 381–386.Kim W.J., Oh Y.M., Sung J. et al. Lung function response to 12-week treatment with combined inhalation of long-acting β2-agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008; 186 (6): 381–386.Umeda N., Yoshikawa T., Kanazawa H. et al. Association of β2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology 2008; 13 (3): 346–352.Umeda N., Yoshikawa T., Kanazawa H. et al. Association of β2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology 2008; 13 (3): 346–352.Mokry M., Joppa P., Slaba E. et al. β2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD. Med. Sci. Monit. 2008; 14 (8): CR392–CR398.Mokry M., Joppa P., Slaba E. et al. β2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD. Med. Sci. Monit. 2008; 14 (8): CR392–CR398.Niu Li+ming, Liang Ying. Effect of polymorphisms in the β2-adrenergic receptor on the susceptibility and pulmonary function of patients with chronic obstructive pulmonary disease: a meta-analysis. Chin. Med. J. 2012; 125 (12): 2213–2218.Niu Li+ming, Liang Ying. Effect of polymorphisms in the β2-adrenergic receptor on the susceptibility and pulmonary function of patients with chronic obstructive pulmonary disease: a meta-analysis. Chin. Med. J. 2012; 125 (12): 2213–2218.Thomsen M., Nordestgaard B.G. β2-adrenergic receptor polymorphisms, asthma and COPD: two large populationbased studies. Eur. Respir. J. 2012; 39: 558–566.Thomsen M., Nordestgaard B.G. β2-adrenergic receptor polymorphisms, asthma and COPD: two large populationbased studies. Eur. Respir. J. 2012; 39: 558–566.Kim W.J., Hersh C.P., DeMeo D.L. et al. Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. Respir. Med. 2009; 103 (4): 552–557.Kim W.J., Hersh C.P., DeMeo D.L. et al. Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. Respir. Med. 2009; 103 (4): 552–557.Lima J.J., Blake K.V., Tantisira K.G., Weiss S.T. Pharmacogenetics of asthma. Curr. Opin. Pulm. Med. 2009; 15 (1): 57–62.Lima J.J., Blake K.V., Tantisira K.G., Weiss S.T. Pharmacogenetics of asthma. Curr. Opin. Pulm. Med. 2009; 15 (1): 57–62.Hawkins G.A., Weiss S.T., Bleecker E.R. Clinical consequences of ADRB2 polymorphisms. Pharmacogenomics 2008; 9 (3): 349–358.Hawkins G.A., Weiss S.T., Bleecker E.R. Clinical consequences of ADRB2 polymorphisms. Pharmacogenomics 2008; 9 (3): 349–358.Bleecker E.R., Meyers D.A. ADRB2 polymorphism and budesonide / formoterol response in chronic obstructive pulmonary disease. Chest. Prepublished online March 1, 2012.Bleecker E.R., Meyers D.A. ADRB2 polymorphism and budesonide / formoterol response in chronic obstructive pulmonary disease. Chest. Prepublished online March 1, 2012.

The authors declare that there are no conflicts of interest present.